Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Payables (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Payables over the past 3 years, most recently at $8.1 million for Q4 2025.

  • Quarterly results put Payables at $8.1 million for Q4 2025, down 23.93% from a year ago — trailing twelve months through Dec 2025 was $8.1 million (down 23.93% YoY), and the annual figure for FY2025 was $8.1 million, down 23.93%.
  • Payables for Q4 2025 was $8.1 million at Tonix Pharmaceuticals Holding, down from $8.5 million in the prior quarter.
  • Over the last five years, Payables for TNXP hit a ceiling of $12.5 million in Q4 2023 and a floor of $3.9 million in Q3 2024.
  • Median Payables over the past 3 years was $8.5 million (2024), compared with a mean of $8.7 million.
  • Peak annual rise in Payables hit 132.37% in 2024, while the deepest fall reached 49.54% in 2024.
  • Tonix Pharmaceuticals Holding's Payables stood at $12.5 million in 2023, then fell by 14.54% to $10.7 million in 2024, then decreased by 23.93% to $8.1 million in 2025.
  • The last three reported values for Payables were $8.1 million (Q4 2025), $8.5 million (Q3 2025), and $11.1 million (Q2 2025) per Business Quant data.